Table 1 Basic characteristics of patients
From: YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance
Characteristic | Low YY1(n = 187) | High YY1(n = 188) | p |
|---|---|---|---|
Age, median (IQR) | 66 (58, 73) | 68 (59, 73) | 0.522 |
Gender, n (%) | Â | Â | 0.718 |
Female | 69 (18.4%) | 65 (17.3%) | Â |
Male | 118 (31.5%) | 123 (32.8%) | Â |
T stage, n (%) | Â | Â | 0.066 |
T1 | 12 (3.3%) | 7 (1.9%) | Â |
T2 | 46 (12.5%) | 34 (9.3%) | Â |
T3 | 86 (23.4%) | 82 (22.3%) | Â |
T4 | 40 (10.9%) | 60 (16.3%) | Â |
N stage, n (%) | Â | Â | 0.159 |
N0 | 64 (17.9%) | 47 (13.2%) | Â |
N1 | 48 (13.4%) | 49 (13.7%) | Â |
N2 | 34 (9.5%) | 41 (11.5%) | Â |
N3 | 31 (8.7%) | 43 (12%) | Â |
M stage, n (%) | Â | Â | 0.398 |
M0 | 168 (47.3%) | 162 (45.6%) | Â |
M1 | 10 (2.8%) | 15 (4.2%) | Â |
Pathologic stage, n (%) | Â | Â | 0.189 |
Stage I | 30 (8.5%) | 23 (6.5%) | Â |
Stage II | 59 (16.8%) | 52 (14.8%) | Â |
Stage III | 69 (19.6%) | 81 (23%) | Â |
Stage IV | 14 (4%) | 24 (6.8%) | Â |
Histological type, n (%) | Â | Â | 0.387 |
Diffuse Type | 36 (9.6%) | 27 (7.2%) | Â |
Mucinous Type | 12 (3.2%) | 7 (1.9%) | Â |
Not Otherwise Specified | 102 (27.3%) | 105 (28.1%) | Â |
Papillary Type | 1 (0.3%) | 4 (1.1%) | Â |
Signet Ring Type | 5 (1.3%) | 6 (1.6%) | Â |
Tubular Type | 31 (8.3%) | 38 (10.2%) | Â |
Histologic grade, n (%) | Â | Â | 0.897 |
G1 | 6 (1.6%) | 4 (1.1%) | Â |
G2 | 69 (18.9%) | 68 (18.6%) | Â |
G3 | 109 (29.8%) | 110 (30.1%) | Â |
Anatomic neoplasm subdivision, n (%) | Â | Â | 0.543 |
Antrum/Distal | 70 (19.4%) | 68 (18.8%) | Â |
Cardia/Proximal | 28 (7.8%) | 20 (5.5%) | Â |
Fundus/Body | 58 (16.1%) | 72 (19.9%) | Â |
Gastroesophageal Junction | 22 (6.1%) | 19 (5.3%) | Â |